These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 12849805)

  • 1. Monitoring of in vitro fertilization-embryo transfer cycles by ultrasound versus by ultrasound and hormonal levels: a prospective, multicenter, randomized study.
    Lass A;
    Fertil Steril; 2003 Jul; 80(1):80-5. PubMed ID: 12849805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of low-dose human chorionic gonadotropin combined with human menopausal gonadotropin protocol on women with hypogonadotropic hypogonadism undergoing ovarian stimulation for in vitro fertilization.
    Jiang S; Kuang Y
    Clin Endocrinol (Oxf); 2018 Jan; 88(1):77-87. PubMed ID: 28960429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study.
    European Recombinant LH Study Group
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2607-18. PubMed ID: 11397861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon).
    de Jong D; Macklon NS; Eijkemans MJ; Mannaerts BM; Coelingh Bennink HJ; Fauser BC;
    Fertil Steril; 2001 Apr; 75(4):688-93. PubMed ID: 11287020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Follicular development and hormonal levels following highly purified or recombinant follicle-stimulating hormone administration in ovulatory women undergoing ovarian stimulation after pituitary suppression for in vitro fertilization: implications for implantation potential.
    Balasch J; Fábregues F; Creus M; Peñarrubia J; Vidal E; Carmona F; Puerto B; Vanrell JA
    J Assist Reprod Genet; 2000 Jan; 17(1):20-7. PubMed ID: 10754779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
    Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
    J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal stimulation IVF using clomiphene citrate and oral contraceptive pill pretreatment for LH suppression.
    Branigan EF; Estes MA
    Fertil Steril; 2000 Mar; 73(3):587-90. PubMed ID: 10689017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of the efficiency of controlled ovarian hyperstimulation in the gonadotropin-releasing hormone agonist-suppression cycle using the initial follicle count during gonadotropin stimulation.
    Huang FJ; Chang SY; Tsai MY; Kung FT; Wu JF; Chang HW
    J Assist Reprod Genet; 2001 Feb; 18(2):91-6. PubMed ID: 11285987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical analysis of assistant treatment proposals for infertile women with polycystic ovary syndrome].
    Chen ZJ; Shi YH; Li Y; Gao Q; Sheng Y; Ma ZX
    Zhonghua Fu Chan Ke Za Zhi; 2008 Aug; 43(8):571-5. PubMed ID: 19087489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of stimulation with clomiphene citrate in combination with recombinant follicle-stimulating hormone and recombinant luteinizing hormone to stimulation with a gonadotropin-releasing hormone agonist protocol: a prospective, randomized study.
    Weigert M; Krischker U; Pöhl M; Poschalko G; Kindermann C; Feichtinger W
    Fertil Steril; 2002 Jul; 78(1):34-9. PubMed ID: 12095487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of the antral follicle count to predict the outcome of assisted reproductive technologies.
    Chang MY; Chiang CH; Hsieh TT; Soong YK; Hsu KH
    Fertil Steril; 1998 Mar; 69(3):505-10. PubMed ID: 9531887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization.
    Schmidt DW; Maier DB; Nulsen JC; Benadiva CA
    Fertil Steril; 2004 Oct; 82(4):841-6. PubMed ID: 15482757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
    Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
    Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI).
    Kwan I; Bhattacharya S; McNeil A; van Rumste MM
    Cochrane Database Syst Rev; 2008 Apr; (2):CD005289. PubMed ID: 18425917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment.
    Yong PY; Brett S; Baird DT; Thong KJ
    Fertil Steril; 2003 Feb; 79(2):308-15. PubMed ID: 12568839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles.
    Daya S; Gunby J
    Cochrane Database Syst Rev; 2000; (4):CD002810. PubMed ID: 11034767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Correlation between serum inhibin B level after treatment with gonadotropin releasing hormone agonist and outcome of in vitro fertilization-embryo transfer].
    Lin WQ; Yang HY; Lin JJ; Chen X; Ye BL
    Zhonghua Fu Chan Ke Za Zhi; 2009 Apr; 44(4):260-2. PubMed ID: 19570462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles.
    Kuang Y; Hong Q; Chen Q; Lyu Q; Ai A; Fu Y; Shoham Z
    Fertil Steril; 2014 Jan; 101(1):105-11. PubMed ID: 24161646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.